ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sanofi and Schrödinger have struck a deal under which Schrödinger will provide computational drug design support to the French drugmaker. Schrödinger could receive up to $120 million under the multiyear agreement. Sanofi intends to take advantage of Schrödinger’s advances in the areas of protein and ligand structure determination and potency prediction. The partners say they will use a new informatics system to facilitate collaboration between computational designers and medicinal chemists.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter